Dr. John Cush RheumNow
3 years 9 months ago
Spondyloarthritis Topic Panel - #ACR22
SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims
@synovialjoints @AkhilSoodMD @ericdeinmd @RHEUMarampa @DrCassySims
https://t.co/uFPW3NxZEm https://t.co/stjmhcFoaS
Dr. John Cush RheumNow
3 years 9 months ago
Women vs. Men: Response to Treatment in Seronegative Arthritis
Dr. Janet Pope ( @Janetbirdope) discusses abstracts 1614 and 1601 at #ACR22
https://t.co/nUFjPr1Zya https://t.co/L47pzS7YXv
Dr. John Cush RheumNow
3 years 9 months ago
Treatment Considerations in Axial Spondyloarthritis
Dr. Lianne Gensler discusses treatment considerations in Axial SpA from #ACR22.
-Abstract 0402
-Abstract 0388
-Abstract 0544
-Abstract 0545
https://t.co/1PvN3SnqHQ https://t.co/i2nyvjyv3D
Dr. John Cush RheumNow
3 years 9 months ago
Updates on Reproductive Health in Women with SLE
Dr. Catherine Sims ( @DrCassySims) summarizes reproductive health abstracts presented at #ACR22.
https://t.co/QxzoBWMexo https://t.co/4wUPKOOemE
Dr. John Cush RheumNow
3 years 9 months ago
Differences in Presentation and Outcomes of Early vs Late Onset PsA
Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies
https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK
Dr. John Cush RheumNow
3 years 9 months ago
Potential new treatment for Sjogren's
Is there finally something new on the horizon in Sjogren’s syndrome?
Dr. Eric Dein. ( @ericdeinmd) discusses studies presented at #ACR22.
https://t.co/YinEPKlJb2 https://t.co/YOsc159GFt
Dr. John Cush RheumNow
3 years 9 months ago
Best of #ACR22 Day 2 in PSA
-Efficacy and Safety Results from BE OPTIMAL in PsA
-JAK inhibitors in rheumatic diseases
-Who is the Winner? Switch vs Cycle in PsA
-Women vs. Men: Response to Treatment in Seronegative Arthritis
and more.
https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y
Dr. John Cush RheumNow
3 years 9 months ago
Topic Podcasts - PsA Part1
Best of PsA on Day 1 #ACR22
https://t.co/uXxUwy6u9G https://t.co/GDDXgcn2EC
Dr. John Cush RheumNow
3 years 9 months ago
SLE, Sex and STDs
Once in a while, I find an abstract at the American College of Rheumatology meeting that can potentially save lives and be implemented in practice now.
Dr. Dao ( @KDAO2011) discusses abstract #0939 presented at #ACR22.
https://t.co/0DtAgzB41G https://t.co/O1z7J0O4c6
Dr. John Cush RheumNow
3 years 9 months ago
TNFi cycling in axSpA: Results from CorEVITAS Registy study
Dr. Rachel Tate ( @uptotate) reviews abstract #1499 presented at #ACR22.
https://t.co/rvzB2RHkAD https://t.co/m3uiXAvZmZ
The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was less well delineated.
Dr. John Cush RheumNow
3 years 9 months ago
JAKi Regulatory Decisions - FDA, EMA, Canada
New download available!
https://t.co/92qbWQbMm3 https://t.co/lEjyjwxYMo
Dr. John Cush RheumNow
3 years 9 months ago
New Treatments for SLE?
Dr. Petri discusses abstract 1117 presented at #ACR22. Efficacy & Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients w/Active SLE: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
https://t.co/nKOserLdbb https://t.co/xhVsxT8BZW
Dr. John Cush RheumNow
3 years 9 months ago
RA Topic Panel
RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan
Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan
https://t.co/GMqRmF2yXA https://t.co/WmYRTp49Rv
Dr. John Cush RheumNow
3 years 9 months ago
Proposed Cancer Screening for Inflammatory Myositis Patients
11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.
https://t.co/JlGGZ6UnOc https://t.co/86OnuLINPy
